CATX (Perspective Therapeutics) Marketable Securities: $216.96 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CATX Perspective Therapeutics Inc CATX
31 GF Score
Price $3.00
! 2 Warning Signs
View Full Analysis

What is Perspective Therapeutics Marketable Securities?

Perspective Therapeutics CATX -0.33% 31 Marketable Securities is $216.96 Mil as of Mar. 2026. GuruFocus rates CATX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Perspective Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $216.96 Mil.

Perspective Therapeutics's annual Marketable Securities stayed the same from Jun. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($165.34 Mil).

Perspective Therapeutics  (AMEX:CATX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Perspective Therapeutics Marketable Securities Related Terms

Perspective Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Marketable Securities Chart

Perspective Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 165.34

Perspective Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.30 162.73 147.38 114.11 216.96
CATX
31GF Score
Perspective Therapeutics Inc CATX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $216.96 Mil mean?
Perspective Therapeutics (CATX) has a Marketable Securities of $216.96 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' Marketable Securities too high?
Perspective Therapeutics' current Marketable Securities is $216.96 Mil. Overall, Perspective Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Marketable Securities compare to CV and LAB?
Perspective Therapeutics' Marketable Securities of $216.96 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Perspective Therapeutics and its competitors. Perspective Therapeutics's current Marketable Securities is $216.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (CATX) has a current Marketable Securities of $216.96 Mil. The current Marketable Securities is $216.96 Mil. Perspective Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Perspective Therapeutics (CATX), the current Marketable Securities is $216.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges AAJ0:Germany
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
31GF Score

Get the complete analysis for CATX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00
Price